Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating ...

M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth ...

RBC Capital lowered the firm’s price target on Neurocrine (NBIX) to $139 from $148 and keeps a Sector Perform rating on the shares. The payer ...

Neurocrine Biosciences (NasdaqGS:NBIX) announced the initiation of a Phase 1 clinical study for the compound NBI-1140675, a new VMAT2 inhibitor. This development could influence investor sentiment, ...

Below is a chart showing MA's trailing twelve month trading history, with the $545 strike highlighted in orange: And Neurocrine Biosciences, Inc. (Symbol: NBIX) saw options trading volume of 6,125 ...

Morgan Stanley assumed coverage of Neurocrine (NBIX) with an Overweight rating and a price target of $150, down from $185. The firm sees ...

In this article, we are going to take a look at where Neurocrine (NASDAQ:NBIX) stands against other top insider stock buys and sells in January. Ever heard of the “January effect?” In case you ...

We recently published a list of 10 Top Insider Stock Buys And Sells In January. In this article, we are going to take a look at where Neurocrine (NASDAQ:NBIX) stands against other top insider stock ...

$NBIX insiders have traded $NBIX stock on the open market 48 times in the past 6 months. Of those trades, 0 have been purchases and 48 have been sales. Here’s a ...

We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against the other ...